04 October 2024
04 October 2024
Novo Nordisk鈥檚 chief scientific officer Marcus Schindler led the keynote address at ELRIG Drug Discovery 2024 in London, UK.
Opdivo has been approved as a perioperative therapy for NSCLC based on data from the CheckMate-77T trial.
The strategic move is set to enhance Recordati's rare diseases franchise.
Pfizer and Merck KGaA鈥檚 venture capital arms were among the backers in the Series B round.
At ELRIG 2024, Dr. Maria Duca described how her lab鈥檚 rational design approach bypasses lengthy screening protocols.
The company plans to use the Series B investment to advance the development of its macrophage therapies in inflammatory and fibrotic indications.
The funding will help secure the supply chain for key starting materials and APIs.
Teva will be responsible for securing regulatory clearances and spearheading the market launch in the designated regions.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
